Synthetic antigenic peptides as a new strategy for immunotherapy of cancer.

E. Appella, D. J. Loftus, K. Sakaguchi, A. Sette, Esteban Celis

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Antigens presented by class I of the major histocompatibility complex (MHC) are recognised by the T cell receptor of CD8+ cytolytic effector cells (CTLs), while class II molecules present antigens to CD4+ helper T cells. For both class I and class II molecules, structure and function are linked through the binding of peptides. Consensus or individual sequences have been obtained for naturally processed peptides bound to a variety of class I and class II molecules, revealing the general features of peptides associated with MHC molecules. The interactions between peptides and MHC molecules have been more clearly defined by the characterization of the three dimensional structure of several different MHC molecules. CTLs have been implicated in immune responses against tumors and it is now well documented that some human tumors express specific antigens, which are recognised by CTLs and could potentially be used in immunotherapy protocols. The use of antigenic peptides to elicit a specific and effective CTL response in vivo offers several advantages over the use of other antigenic moieties. Emerging strategies for the safe and effective administration of peptides to humans may lead to their use in the immunological prevention and treatment of cancer.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalBiomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity
Volume1
Issue number3
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Immunotherapy
Major Histocompatibility Complex
Peptides
Neoplasms
CD4 Antigens
Histocompatibility Antigens Class I
Helper-Inducer T-Lymphocytes
T-Cell Antigen Receptor
Antigens

Cite this

Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. / Appella, E.; Loftus, D. J.; Sakaguchi, K.; Sette, A.; Celis, Esteban.

In: Biomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity, Vol. 1, No. 3, 01.01.1995, p. 177-184.

Research output: Contribution to journalReview article

@article{d7735a4675aa486291495435a31a73a9,
title = "Synthetic antigenic peptides as a new strategy for immunotherapy of cancer.",
abstract = "Antigens presented by class I of the major histocompatibility complex (MHC) are recognised by the T cell receptor of CD8+ cytolytic effector cells (CTLs), while class II molecules present antigens to CD4+ helper T cells. For both class I and class II molecules, structure and function are linked through the binding of peptides. Consensus or individual sequences have been obtained for naturally processed peptides bound to a variety of class I and class II molecules, revealing the general features of peptides associated with MHC molecules. The interactions between peptides and MHC molecules have been more clearly defined by the characterization of the three dimensional structure of several different MHC molecules. CTLs have been implicated in immune responses against tumors and it is now well documented that some human tumors express specific antigens, which are recognised by CTLs and could potentially be used in immunotherapy protocols. The use of antigenic peptides to elicit a specific and effective CTL response in vivo offers several advantages over the use of other antigenic moieties. Emerging strategies for the safe and effective administration of peptides to humans may lead to their use in the immunological prevention and treatment of cancer.",
author = "E. Appella and Loftus, {D. J.} and K. Sakaguchi and A. Sette and Esteban Celis",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "177--184",
journal = "Biomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity",
issn = "1353-8616",
number = "3",

}

TY - JOUR

T1 - Synthetic antigenic peptides as a new strategy for immunotherapy of cancer.

AU - Appella, E.

AU - Loftus, D. J.

AU - Sakaguchi, K.

AU - Sette, A.

AU - Celis, Esteban

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Antigens presented by class I of the major histocompatibility complex (MHC) are recognised by the T cell receptor of CD8+ cytolytic effector cells (CTLs), while class II molecules present antigens to CD4+ helper T cells. For both class I and class II molecules, structure and function are linked through the binding of peptides. Consensus or individual sequences have been obtained for naturally processed peptides bound to a variety of class I and class II molecules, revealing the general features of peptides associated with MHC molecules. The interactions between peptides and MHC molecules have been more clearly defined by the characterization of the three dimensional structure of several different MHC molecules. CTLs have been implicated in immune responses against tumors and it is now well documented that some human tumors express specific antigens, which are recognised by CTLs and could potentially be used in immunotherapy protocols. The use of antigenic peptides to elicit a specific and effective CTL response in vivo offers several advantages over the use of other antigenic moieties. Emerging strategies for the safe and effective administration of peptides to humans may lead to their use in the immunological prevention and treatment of cancer.

AB - Antigens presented by class I of the major histocompatibility complex (MHC) are recognised by the T cell receptor of CD8+ cytolytic effector cells (CTLs), while class II molecules present antigens to CD4+ helper T cells. For both class I and class II molecules, structure and function are linked through the binding of peptides. Consensus or individual sequences have been obtained for naturally processed peptides bound to a variety of class I and class II molecules, revealing the general features of peptides associated with MHC molecules. The interactions between peptides and MHC molecules have been more clearly defined by the characterization of the three dimensional structure of several different MHC molecules. CTLs have been implicated in immune responses against tumors and it is now well documented that some human tumors express specific antigens, which are recognised by CTLs and could potentially be used in immunotherapy protocols. The use of antigenic peptides to elicit a specific and effective CTL response in vivo offers several advantages over the use of other antigenic moieties. Emerging strategies for the safe and effective administration of peptides to humans may lead to their use in the immunological prevention and treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029420201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029420201&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 177

EP - 184

JO - Biomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity

JF - Biomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity

SN - 1353-8616

IS - 3

ER -